WO2005013909A3 - Nouveaux inhibiteurs de la cathepsine k - Google Patents

Nouveaux inhibiteurs de la cathepsine k Download PDF

Info

Publication number
WO2005013909A3
WO2005013909A3 PCT/US2004/025645 US2004025645W WO2005013909A3 WO 2005013909 A3 WO2005013909 A3 WO 2005013909A3 US 2004025645 W US2004025645 W US 2004025645W WO 2005013909 A3 WO2005013909 A3 WO 2005013909A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
directed
treatment
pharmaceutical composition
methods
Prior art date
Application number
PCT/US2004/025645
Other languages
English (en)
Other versions
WO2005013909A2 (fr
Inventor
Jae U Jeong
Original Assignee
Smithkline Beecham Corp
Jae U Jeong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Jae U Jeong filed Critical Smithkline Beecham Corp
Publication of WO2005013909A2 publication Critical patent/WO2005013909A2/fr
Publication of WO2005013909A3 publication Critical patent/WO2005013909A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des nouvelles oxo-amino-sulfonyl-azapanes. Plus précisément, l'invention a trait à des composés représentés par la formule (I), dans laquelle R1, R2, et R3 sont tels que définis dans le descriptif de l'invention, et à des sels pharmaceutiquement acceptables de ces derniers. Les composés selon l'invention sont des inhibiteurs de protéase, et peuvent être utiles pour traiter des troubles dont le caractère pathologique peut être modifié thérapeutiquement par l'inhibition d'une cystéine ou d'une sérine protéase de la superfamille de la papaïne, en particulier la cathepsine K. Par conséquent, l'invention concerne également des compositions pharmaceutiques contenant un composé selon l'invention. L'invention a aussi pour objet des méthodes de traitement de troubles caractérisés par la perte osseuse, notamment l'ostéoporose et les maladies des gencives, et par la dégradation excessive du cartilage ou de la matrice, notamment l'ostéoarthrose et la polyarthrite rhumatoïde, à l'aide d'un composé selon l'invention ou d'une composition contenant le composé selon l'invention. L'invention se rapporte également à des méthodes de traitement de certaines parasitoses telles que la malaria à l'aide d'un composé selon l'invention ou d'une composition pharmaceutique contenant un composé selon l'invention.
PCT/US2004/025645 2003-08-07 2004-08-04 Nouveaux inhibiteurs de la cathepsine k WO2005013909A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49331403P 2003-08-07 2003-08-07
US60/493,314 2003-08-07

Publications (2)

Publication Number Publication Date
WO2005013909A2 WO2005013909A2 (fr) 2005-02-17
WO2005013909A3 true WO2005013909A3 (fr) 2005-08-18

Family

ID=34135226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025645 WO2005013909A2 (fr) 2003-08-07 2004-08-04 Nouveaux inhibiteurs de la cathepsine k

Country Status (1)

Country Link
WO (1) WO2005013909A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057836A1 (es) 2005-10-21 2007-12-19 Actelion Pharmaceuticals Ltd Piperizinas como agentes contra la malaria
US8889688B2 (en) 2010-01-05 2014-11-18 Actelion Pharmaceuticals Ltd. Piperazines as antimalarial agents
WO2014141175A1 (fr) 2013-03-15 2014-09-18 Actelion Pharmaceuticals Ltd Nouveaux dérivés d'acrylamide comme agents antipaludiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017924A1 (fr) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Procede de traitement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017924A1 (fr) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Procede de traitement

Also Published As

Publication number Publication date
WO2005013909A2 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
ATE409482T1 (de) Cathepsincystein-proteasehemmer
ATE395911T1 (de) Cathepsin-cystein-protease-hemmer
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
EA200400606A1 (ru) ИНГИБИТОРЫ ФАКТОРА Ха И ДРУГИХ СЕРИНОВЫХ ПРОТЕАЗ, ВОВЛЕЧЁННЫХ В КОАГУЛЯЦИОННЫЙ КАСКАД
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
WO2005028429A3 (fr) Composes contenant un haloalkyle utilise comme inhibiteurs de cysteine protease
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
TW200631576A (en) Cathepsin cysteine protease inhibitors
NO20045042L (no) 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer
WO2006055434A3 (fr) Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
EP1902031A4 (fr) Inhibiteurs de cystéine protéases de type cathepsine
DE60231207D1 (de) Inhibitoren
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
WO2002080853A3 (fr) Inhibiteurs heterocycliques fusionnes du facteur xa
ECSP024388A (es) Inhibidores de proteasas
WO2005013909A3 (fr) Nouveaux inhibiteurs de la cathepsine k
WO2004094441A3 (fr) Nouveaux composes d'acide phosphonique utilises comme inhibiteurs des serine proteases
AU2003230772A1 (en) Cyanamides useful as reversible inhibitors of cysteine proteases
WO2002070517A3 (fr) Inhibiteurs de cysteine protease de type cathepsine
WO2003053331A3 (fr) Inhibiteurs de la protease
WO2005034838A3 (fr) Inhibiteurs de proteases
WO2003104257A3 (fr) Inhibiteurs de proteases
WO2003090737A3 (fr) Methodes et compositions de traitement de la douleur cancereuse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase